AtaCor completes enrollment in implantable cardioverter defibrillator study

AtaCor Medical announced that it completed enrollment in its initial acute extravascular implantable cardioverter defibrillator (EV-ICD) study.

San Clemente, California-based AtaCor’s PASS-PULL EV-ICD study will evaluate the company’s EV-ICD lead in connection with commercially available ICDs.

According to a news release, AtaCor designed its novel EV-ICD to provide both shock and anti-tachycardia pacing therapies to treat life-threatening tachyarrhythmias and pacing therapies to treat bradycardia with aims to reducing dependency on transvenous ICD leads and the complications associated with them.

The AtaCor custom delivery tool aids in the insertion of the lead through a rib space at the left sternal margin above the heart. The final lead position is adjacent to the sternum, leaving the heart completely untouched.

PASS-PULL EV-ICD will evaluate the delivery of AtaCor’s EV-ICD lead and its acute defibrillation success. The study e…

Read more
  • 0

20 medical device startups you need to know

The medtech industry isn’t immune from COVID-19 troubles, but exciting innovation continues. These 20 medical device startups have grabbed our attention.

Tom Salemi, DeviceTalks Editorial Director and Sean Whooley, Assistant Editor

A number of medical device startups continue to make waves across the space, with new technologies and eye-watering fundraising rounds highlighting some exciting prospects.

From treating children with congenital heart disease to therapy that alleviates the effects of traumatic nightmares — and with plenty more innovations between — there is no shortage of intriguing medical devices and therapies coming up through the ranks.

“Even in the face of the COVID-19 pandemic, we continue to see tremendous energy in the medtech innovation ecosystem,” said Paul Grand, CEO of MedTech Innovator. “We are noticing a strong trend of minimally invasive medical devices that improve patient outcomes and require less time spent in th…

Read more
  • 0